Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2026 Sep 23;11:403. doi: 10.1038/s41392-026-02954-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2026

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 5 — PARPi approved for marketing. Six PARPi have been approved for cancer treatment: olaparib (Lynparza® from AstraZeneca), niraparib (Zejula® from GlaxoSmithKline), rucaparib (Rubraca® from Pharmaand GmbH), talazoparib (Talzenna® from Pfizer), and only in China, fuzuloparib (AiRuiYi® from Jiangsu Hengrui Pharmaceuticals) and pamiparib (Partruvix® from BeiGene). These drugs, except fuzuloparib and pamiparib, are currently approved by the FDA and the EMA for treating cancers such as breast, ovarian, prostate and pancreatic cancer. Fuzuloparib (formerly fluzoparib) received approval in 2021 by the NMPA for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer). Also in 2021, pamiparib was approved by the NMPA for gBRCA1/2m recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy. Several clinical trials of these drugs directed to the expansion of their indications are ongoing. The different PARPi display distinct degrees of PARP trapping: talazoparib » niraparib > olaparib = rucaparib. Although backed by less evidence, fuzuloparib harbors similar trapping capacity compared to olaparib, and pamiparib similar or higher level. Figure created with BioRender